
ATLANTA, July 29, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Grail, Inc. (“Grail”) (NASDAQ: GRAL). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding the probability of achieving the primary endpoint of a statistically significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial.










